The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...
Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...
Archbow Consulting announced Justine Hughes has been promoted to EVP of principal operations while Honora Gabriel and Rob ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil ...
Hosted on MSN1d
Amgen price target lowered to $295 from $310 at CitiCiti lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...
13d
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback